Cost-effectiveness analysis of sarcopenia management interventions in Iran

被引:1
|
作者
Darvishi, Ali [1 ,2 ]
Shafiee, Gita [1 ]
Balajam, Narges Zargar [3 ]
Hemami, Mohsen Rezaei [4 ]
Ostovar, Navid [1 ]
Heshmat, Ramin [1 ,3 ]
机构
[1] Univ Tehran Med Sci, Chron Dis Res Ctr, Endocrinol & Metab Populat Sci Inst, 10 Jalale Al Ahmad Ave,Chamran Highway, Tehran 1411713137, Iran
[2] Univ Tehran Med Sci, Sch Publ Hlth, Dept Hlth Management & Econ, Tehran, Iran
[3] Univ Tehran Med Sci, Endocrinol & Metab Res Ctr, Endocrinol & Metab Populat Sci Inst, Tehran, Iran
[4] Perspectum Ltd, Oxford, England
关键词
Sarcopenia; Management intervention; Economic evaluation; Cost-Utility Analysis (CUA); Quality-adjusted life years (QALYs); SKELETAL-MUSCLE STRENGTH; VITAMIN-D; IMPACT; SUPPLEMENTATION; ASSOCIATION; MORTALITY; ADULTS; MASS;
D O I
10.1186/s12889-023-15693-w
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objectives Identification the optimal management intervention of sarcopenia is a concern of health systems. We aimed to analyze the cost-effectiveness of sarcopenia management strategies in Iran. Methods We constructed a lifetime Markov model based on natural history. The strategies comparedincluded exercise training, nutritional supplements, whole body vibration ( WBV), and various exercise interventions and nutritional supplement combinations. A total of 7 strategies was evaluated in addition to the non-intervention strategy. Parameter values were extracted from primary data and the literature, and the costs and Quality-adjusted life years (QALYs) were calculated for each strategy. Deterministic and probabilistic sensitivity analysis, including the expected value of perfect information (EVPI), was also performed to determine the robustness of the model. Analyses were performed using the 2020 version of TreeAge Pro software. Results All seven strategies increased lifetime effectiveness (QALYs). The protein and Vitamin D-3 (P + D) strategy had the highest effectiveness values among all strategies. After removing the dominated strategies, the estimated ICER for the P + D compared to Vitamin D-3 alone (D) strategy was calculated as $131,229. Considering the cost-effectiveness threshold ($25,249), base-case results indicated that the D strategy was the most cost-effective strategy in this evaluation. Sensitivity analysis of model parameters also demonstrated the robustness of results. Also, EVPI was estimated at $273. Conclusions Study results, as the first economic evaluation of sarcopenia management interventions, showed that despite the higher effectiveness of D + P, the D strategy was the most cost-effective. Completing clinical evidence of various intervention options can lead to more accurate results in the future.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Sustainability of Behavioral Interventions: Beyond Cost-Effectiveness Analysis
    Paul M. Brown
    Linda D. Cameron
    Steven Ramondt
    [J]. International Journal of Behavioral Medicine, 2015, 22 : 425 - 433
  • [22] Cost-effectiveness analysis in the economic assessment of health interventions
    Prieto, L
    Sacristán, JA
    Antoñanzas, F
    Rubio-Terrès, C
    Pinto, JL
    Rovira, J
    Grupo, ECOMED
    [J]. MEDICINA CLINICA, 2004, 122 (13): : 505 - 510
  • [23] A COST-EFFECTIVENESS ANALYSIS OF INTERVENTIONS FOR SYMPTOMATIC VARICOSE VEINS
    Marsden, G.
    Perry, M.
    Bradbury, A.
    Hickey, N.
    Kelley, K.
    Trender, H.
    Wonderling, D.
    Davies, A. H.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A488 - A489
  • [24] The Importance of Model Structure in the Cost-Effectiveness Analysis of Primary Care Interventions for the Management of Hypertension
    Penaloza-Ramos, Maria Cristina
    Jowett, Sue
    Sutton, Andrew John
    McManus, Richard J.
    Barton, Pelham
    [J]. VALUE IN HEALTH, 2018, 21 (03) : 351 - 363
  • [25] The comparative effectiveness and cost-effectiveness of vitreoretinal interventions
    Brown, Melissa M.
    Brown, Gary C.
    Brown, Heidi C.
    Irwin, Blair
    Brown, Kathryn S.
    [J]. CURRENT OPINION IN OPHTHALMOLOGY, 2008, 19 (03) : 202 - 207
  • [26] Effectiveness; and cost-effectiveness of antidepressants and psychological interventions
    Perestelo-Perez, Lilisbeth
    Garcia-Perez, Lidia
    Penate-Castro, Wenceslao
    de las Cuevas-Castresana, Carlos
    [J]. INTERNATIONAL JOURNAL OF PSYCHOLOGY, 2008, 43 (3-4) : 649 - 649
  • [27] Remote Health Interventions: Effectiveness, Cost, and Cost-Effectiveness Considerations
    Williams, Austin M.
    Gift, Thomas L.
    [J]. SEXUALLY TRANSMITTED DISEASES, 2022, 49 (11S) : S15 - S17
  • [28] Intensive case management: a cost-effectiveness analysis
    Johnston, S
    Salkeld, G
    Sanderson, K
    Issakidis, C
    Teesson, M
    Buhrich, N
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 1998, 32 (04): : 551 - 559
  • [29] Febuxostat in the management of gout: a cost-effectiveness analysis
    Smolen, Lee J.
    Gahn, James C.
    Mitri, Ghaith
    Shiozawa, Aki
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (03) : 265 - 276
  • [30] COST-EFFECTIVENESS ANALYSIS OF DIABETIC NEPHROPATHY MANAGEMENT
    Alenzi, E. O.
    Kamal, K.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A204 - A204